Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price dropped 3.5% during mid-day trading on Thursday . The stock traded as low as $202.85 and last traded at $205.25. Approximately 1,618 shares changed hands during trading, a decline of 41% from the average daily volume of 2,749 shares. The stock had previously closed at $212.80.
Genmab A/S Stock Down 2.1 %
The stock’s 50 day simple moving average is $220.80 and its 200 day simple moving average is $248.86.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- What is a SEC Filing?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Where to Find Earnings Call Transcripts
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Breakout Stocks: What They Are and How to Identify Them
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
